Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Benchmark Holdings plc (BMK) Ordinary Shares

Sell:45.00p Buy:48.00p 0 Change: No change
FTSE AIM 100:2.23%
Market closed Prices as at close on 13 December 2019 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:45.00p
Buy:48.00p
Change: No change
Market closed Prices as at close on 13 December 2019 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:45.00p
Buy:48.00p
Change: No change
Market closed Prices as at close on 13 December 2019 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Benchmark Holdings plc is engaged in the provision of aquaculture health, genetics and nutrition. The Company’s segments include genetics, advanced nutrition and health. The Company develops products that helps fish and shrimp to improve their sustainability and profitability by improving yield, quality, and by reducing mortality. The Company’s products include high genetic quality ova for salmon, shrimp and tilapia, and breeding, program, specialist feeds for early stage shrimp and fish; probiotics, Vaccines, biocides, and medicines.

Contact details

Address:
Benchmark House, 8 Smithy Wood Drive
SHEFFIELD
S35 1QN
United Kingdom
Telephone:
+44 (0114) 2409939
Website:
www.benchmarkplc.com/

Important dates

Future events
Final results 20 December 2019 20/12/19
Past events
Trading Announcement 29 November 2019 29/11/19
Trading Announcement 12 August 2019 12/08/19
Interim results 25 June 2019 25/06/19
Trading Announcement 03 June 2019 03/06/19
AGM 14 March 2019 14/03/19
Annual report 29 January 2019 29/01/19
Final results 24 January 2019 24/01/19

General stock information

EPIC:
BMK
ISIN:
GB00BGHPT808
Market cap:
£259.92 million
Shares in issue:
558.96 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE AIM 100,FTSE AIM All Share

Key personnel

  • Peter George
    Executive Chairman of the Board
  • Septima Maguire
    Chief Financial Officer
  • Alex Raeber
    Chief Scientific Officer
  • James Banfield
    Head of Technical Publishing, Managing Director - 5M Publishing
  • Pierre Hugo
    Finance Director of INVE
  • Jan-Emil Johannessen
    Managing Director of SalmoBreed
  • Patrick Lavens
    Innovations Director of INVE
  • Ruth Layton
    Benchmark Co-founder, Head of Benchmark Sustainability Science
  • Philippe Leger
    Chief Executive Officer of INVE
  • Stelios Leontios
    Commercial Director of INVE

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.